An overview of persistent chylomicronemia: much more than meets the eye.

• Tác giả: Christie Ballantyne, Daniel Gaudet, Miriam Larouche, Gerald F Watts
• Ngôn ngữ: eng
• Ký hiệu phân loại: 936 Europe north and west of Italian Peninsula to ca. 499
• Thông tin xuất bản: England : Current opinion in endocrinology, diabetes, and obesity , 2025
• Bộ sưu tập: NCBI
• ID: 472

Tóm tắt

PURPOSE OF REVIEW: The aim of this review is to provide an overview of severe hypertriglyceridemia presenting in the form of chylomicronemia that persists despite treatment of secondary causes and the use of conventional lipid-lowering treatment. RECENT FINDINGS: Persistent chylomicronemia is a rare syndromic disorder that affects carriers of bi-allelic combinations of pathogenic gene variants impairing lipoprotein lipase (LPL) activity, as well as a significant number of individuals who do not meet this genetic criterion. It is associated with a high risk of acute pancreatitis and other morbidities. Effective innovative treatments for severe hypertriglyceridemia are being developed and are becoming available. Patients with persistent chylomicronemia of any cause respond equally to next-generation therapies with LPL-independent mechanisms of action and do not generally respond to conventional LPL-dependent treatments. SUMMARY: Not all individuals with persistent chylomicronemia carry a proven pathogenic combination of gene variants that impair LPL activity. Documenting the clinical characteristics of people with persistent chylomicronemia and their response to emerging therapies is essential to correctly establish their risk trajectory and ensure equitable access to personalized treatment.